Diamantina Institute for Cancer, Immunology and Metabolic Medicine, University of Queensland
The University of Queensland Diamantina Institute (UQDI) has a strong focus on translational research in both the clinical and basic science of cancer and disorders of immune regulation. The Instute comprises a modern research facility with lead by Professor Matthew Brown, and hosts over 200 researchers, students and support staff. It lays claim to global, world-changing discoveries, such as the world’s first cervical cancer vaccine.
UQDI is based at the Translational Research Institute (TRI) on the Princess Alexandra Hospital campus, which facilitates strong clinical interactions. The TRI provides world-class facilities, which allow researchers to conduct cutting edge research.
The TRI also affords UQDI researchers the opportunity for a much greater collaborative research environment, allowing our researchers to focus their efforts on turning their scientific discoveries into better treatments for diseases including a variety of cancers, osteoporosis, arthritis and other autoimmune diseases.
